Xin Lang Cai Jing·2025-10-13 01:41Group 1 - The core viewpoint of the news is that Nocera Biopharma experienced a significant drop in stock price, with a 9.16% decline on October 10, 2023, and a trading volume of 490 million yuan [1] - On the same day, Nocera Biopharma had a financing buy-in amount of 50.08 million yuan, with a net financing buy of 16.32 million yuan, indicating strong investor interest despite the stock price drop [1] - The total financing and securities balance for Nocera Biopharma reached 287 million yuan, accounting for 4.40% of its circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1] Group 2 - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2] - The company's revenue composition shows that 87.67% comes from drug sales, 12.04% from technology licensing, and minimal contributions from testing and research services [2] - For the first half of 2025, Nocera Biopharma reported a revenue of 731 million yuan, representing a year-on-year growth of 74.26%, while the net profit attributable to shareholders was -30.09 million yuan, an increase of 88.51% compared to the previous period [2] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Nocera Biopharma included several funds, with notable changes in holdings, such as an increase of 3.98 million shares by China Europe Medical Health Mixed A [3] - New entrants among the top shareholders include E Fund Innovative Medicine Mixed A and Yifangda Medical Health Industry Mixed A, indicating a shift in institutional interest [3] - The exit of certain funds like Xingquan Helun Mixed A and Ping An Medical Health Mixed A from the top ten shareholders suggests a reallocation of investment strategies among institutional investors [3]